Individuals who received Johnson & Johnson's COVID-19 vaccine will have a stronger neutralizing antibody response if they get a Messenger RNA (mRNA) shot as the second dose, Axios reported on Tuesday, citing a person who has seen data collected by the U.S. National Institutes of Health.
Johnson & Johnson has asked the U.S. Food and Drug Administration to approve a shot of its own single-dose vaccine as the booster dose. The FDA's advisers are set to consider the need on Friday.
The National Institute of Health (NIH) will present the mix-and-match data to the FDA panel on Friday, Axios said. There were limitations to the NIH data, according to the report. Neutralizing antibodies only prevent the virus from entering cells and replicating, and the report said it was unclear how long the response will last.
The health regulator's outside experts will also talk over the need for an additional dose of Moderna's vaccine on Friday. Scientists at the FDA have said Moderna had not met all of the agency's criteria to support the use of booster doses of its COVIDvaccine, probably because the efficacy of the shot's first two doses has remained strong.